文档下载 文档下载导航
设为首页 | 加入收藏
搜索 请输入内容:  
 导航当前位置: 文档下载 > 所有分类 > 医药卫生 > 临床医学 > Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
侵权投诉

Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer

Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer

rastuzumab, a monoclonal anti-body targeting the extracellular domain ofthe HER2 protein, was approved in 1998

as a first-line treatment in combination with pacli-taxel for HER2-positive metastatic breast cancer.1The benefit of this approach in patients with meta-static disease and the poor prognosis of HER2-pos-itive breast cancer2,3 motivated the National Can-cer Institute (NCI) to sponsor two trials of adjuvanttreatment with trastuzumab, led by the NationalSurgical Adjuvant Breast and Bowel Project (NSABP)and the North Central Cancer Treatment Group(NCCTG).

NSABP trial B-31, which began accrual in Febru-ary 2000, compares four cycles of doxorubicin andcyclophosphamide followed by paclitaxel (group 1)with the same chemotherapy plus 52 weeks of tras-tuzumab beginning on day 1 of paclitaxel therapy(group 2). NCCTG trial N9831 began enrollmentin May 2000 and compares three regimens: fourcycles of doxorubicin and cyclophosphamide fol-lowed by weekly paclitaxel for 12 weeks (group A),four cycles of doxorubicin and cyclophosphamidefollowed by 52 weeks of trastuzumab after the com-pletion of paclitaxel therapy (group B), and fourcycles of doxorubicin and cyclophosphamide fol-lowed by 52 weeks of trastuzumab beginning onday 1 of paclitaxel therapy (group C).

The control groups of the trials, as well as group2 in trial B-31 and group C in trial N9831, differedin terms of the scheduling of paclitaxel treatmentand some aspects of hormonal therapy and radio-therapy but were otherwise identical. For this rea-son, the NCI and the Food and Drug Administra-tion approved a joint-analysis plan developed by theNSABP and NCCTG to combine data from group 1and group A (referred to as the control group) forcomparison with group 2 and group C (referred toas the trastuzumab group). Group B of trial N9831was excluded because the protocol required tras-tuzumab to be administered after the completionof chemotherapy.

The plan required a first interim analysis afterthe occurrence of 355 events. Before the data werelocked, 2043 patients (of a planned total of 2700)were enrolled in trial B-31 and 1633 patients (of atotal of 2000 for the comparison of group A withgroup C) were enrolled in trial N9831. In April 2005,the independent data-monitoring committees ofeach trial recommended closing enrollment andreleasing the results.

t

The new england journal of medicine

Enrollment required a pathological diagnosis ofadenocarcinoma of the breast with immunohisto-chemical staining for HER2 protein of 3+ intensityor amplification of the HER2 gene on fluorescencein situ hybridization. Initially, both trials requiredpatients to have histologically proven, node-posi-tive disease; as of May 2, 2003, patients with high-risk node-negative disease (defined as a tumor thatwas more than 2 cm in diameter and positive forestrogen receptors or progesterone receptors oras a tumor that was more than 1 cm in diameterand negative for both estrogen receptors and pro-gesterone receptors) were eligible for trial N9831.Other requirements were adequate hematopoiet-ic, hepatic, and renal function and a left ventricu-lar ejection fraction (LVEF) that met or exceededthe lower limit of normal. Patients with clinical orradiologic evidence of metastatic disease were ex-cluded. Findings suggestive of metastasis were con-firmed or refuted by additional radiologic evalua-tion or biopsy. Complete resection of the primarytumor and axillary-node dissection were required(negative sentinel-node biopsy was allowed in trialN9831). Patients were ineligible if they had anginapectoris requiring antianginal medication, arrhyth-mia requiring medication, a severe conduction ab-normality, clinically significant valvular disease,cardiomegaly on chest radiography, left ventricularhypertrophy on echocardiography (trial B-31 only),poorly controlled hypertension, clinically signifi-cant pericardial effusion (trial N9831 only), or ahistory of myocardial infarction, congestive heartfailure, or cardiomyopathy.

Participating institutions obtained the approvalof their human investigations committee or insti-tutional review board and filed assurances with theDepartment of Health and Human Services. Writ-ten informed consent was required for enrollment.In trial B-31, treatment assignments were bal-anced according to nodal status, the planned hor-monal therapy, the type of surgery (lumpectomy vs.mastectomy), the intended radiotherapy, and insti-tution with the use of a biased-coin minimizationalgorithm.4 Trial N9831 used a dynamic allocationprocedure that balanced the marginal distributionsof nodal status and hormone-receptor status be-tween groups.5 The procedures used for HER2 test-ing in the two trials are provided in the Supple-

1674n engl j med 353;16

doc.guandang.net

october 20, 2005

上一页第2页

你可能喜欢

热门文档

相关文档

站点地图 | 文档上传 | 侵权投诉 | 手机版
本站所有资源均来自互联网,本站只负责收集和整理,均不承担任何法律责任,如有侵权等其它行为请联系我们.
文档下载 Copyright 2013 doc.guandang.net All Rights Reserved.  -  email